Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

20032,238 citationsJournal Articlebronze Open Access

Authors

Cynthia G. Whitney · National Center for Infectious Diseases

Monica M. Farley · Emory University

James L. Hadler · Connecticut Department of Public Health

Lee H. Harrison · Johns Hopkins University

Nancy M. Bennett

Ruth Lynfield · Minnesota Department of Health

Arthur Reingold · University of California, Berkeley

Abstract

The use of the pneumococcal conjugate vaccine is preventing disease in young children, for whom the vaccine is indicated, and may be reducing the rate of disease in adults. The vaccine provides an effective new tool for reducing disease caused by drug-resistant strains.

Topics & Keywords

Pneumonia and Respiratory Infections Respiratory viral infections research Bacterial Infections and Vaccines

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 348, Issue 18, pp. 1737-1746

DOI: 10.1056/nejmoa022823

Field-Weighted Citation Impact: 95.18